日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Loss of SETD2-mediated downregulation of intracellular and exosomal miRNA-10b determines MAPK pathway activation and multidrug resistance in renal cancer

SETD2 介导的细胞内和外泌体 miRNA-10b 下调的缺失决定了肾癌中的 MAPK 通路激活和多药耐药性

Libin Yan, Siyue Liu, Guoliang Sun, Beichen Ding, Zhize Wang, Heng Li

Transcription Factors BARX1 and DLX4 Contribute to Progression of Clear Cell Renal Cell Carcinoma via Promoting Proliferation and Epithelial-Mesenchymal Transition

转录因子 BARX1 和 DLX4 通过促进增殖和上皮-间质转化促进透明细胞肾细胞癌的进展

Guoliang Sun, Yue Ge, Yangjun Zhang, Libin Yan, Xiaoliang Wu, Wei Ouyang, Zhize Wang, Beichen Ding, Yucong Zhang, Gongwei Long, Man Liu, Runlin Shi, Hui Zhou, Zhiqiang Chen, Zhangqun Ye

Formation and optimization of three-dimensional organoids generated from urine-derived stem cells for renal function in vitro

尿源干细胞三维类器官的形成与优化及其在体外肾功能中的应用

Guoliang Sun, Beichen Ding, Meimei Wan, Liang Chen, John Jackson, Anthony Atala

Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma

抑制 SMYD2 可通过下调 microRNA-125b 来抑制肿瘤进展并减弱肾细胞癌的多药耐药性

Libin Yan, Beichen Ding, Haoran Liu, Yangjun Zhang, Jin Zeng, Junhui Hu, Weimin Yao, Gan Yu, Ruihua An, Zhiqiang Chen, Zhangqun Ye, Jinchun Xing, Kefeng Xiao, Lily Wu, Hua Xu

The Immune Checkpoint Regulator PDL1 is an Independent Prognostic Biomarker for Biochemical Recurrence in Prostate Cancer Patients Following Adjuvant Hormonal Therapy

免疫检查点调节剂 PDL1 是前列腺癌患者辅助激素治疗后生化复发的独立预后生物标志物

Heng Li, Zhize Wang, Yucong Zhang, Guoliang Sun, Beichen Ding, Libin Yan, Haoran Liu, Wei Guan, Zhiquan Hu, Shaogang Wang, Fei Cheng, Hua Xu, Xu Zhang, Zhangqun Ye